We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Oxford Gene Technology Grants Microarray Licence to Phalanx Biotech Group
News

Oxford Gene Technology Grants Microarray Licence to Phalanx Biotech Group

Oxford Gene Technology Grants Microarray Licence to Phalanx Biotech Group
News

Oxford Gene Technology Grants Microarray Licence to Phalanx Biotech Group

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oxford Gene Technology Grants Microarray Licence to Phalanx Biotech Group"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oxford Gene Technology(OGT) and Phalanx Biotech Group have announced the completion of a licensing agreement granting Phalanx access to OGT’s “Southern array patents”, the fundamental patents covering the manufacture and marketing of oligonucleotide microarrays.

The granted licence will enable Phalanx Biotech to fabricate and sell arrays, including OneArray™ for gene expression profile studies, in the US.

Dr Michael Bennett, Vice President Licensing and Patents at OGT, said: “This is a significant deal as it is the first licence granted to a Taiwanese company and reflects OGT’s continuing portfolio expansion in Asia”.

Dr Luke Chen, Vice President of Sales & Marketing at Phalanx Biotech, added, “We have long admired the work of Professor Edwin Southern and this important agreement will help Phalanx Biotech in its mission to provide affordable microarray products to scientists for new gene expression studies and to validate their existing microarray results.”

The licence will remain valid for the patents’ lifetime. Financial details were not disclosed.

Advertisement